Order Article Reprints

Hori R, Shinohara S, Kojima T, Kagoshima H, Kitamura M, Tateya I, Tamaki H, Kumabe Y, Asato R, Harada H, et al. Real-World Outcomes and Prognostic Factors in Patients Receiving Nivolumab Therapy for Recurrent or Metastatic Head and Neck Carcinoma. Cancers. 2019; 11(9):1317. https://doi.org/10.3390/cancers11091317

Hori, Ryusuke, Shogo Shinohara, Tsuyoshi Kojima, Hiroki Kagoshima, Morimasa Kitamura, Ichiro Tateya, Hisanobu Tamaki, Yohei Kumabe, Ryo Asato, Hiroyuki Harada, and et al. 2019. "Real-World Outcomes and Prognostic Factors in Patients Receiving Nivolumab Therapy for Recurrent or Metastatic Head and Neck Carcinoma" Cancers 11, no. 9: 1317. https://doi.org/10.3390/cancers11091317

Hori, R., Shinohara, S., Kojima, T., Kagoshima, H., Kitamura, M., Tateya, I., Tamaki, H., Kumabe, Y., Asato, R., Harada, H., Kitani, Y., Tsujimura, T., Honda, K., Ichimaru, K., & Omori, K. (2019). Real-World Outcomes and Prognostic Factors in Patients Receiving Nivolumab Therapy for Recurrent or Metastatic Head and Neck Carcinoma. Cancers, 11(9), 1317. https://doi.org/10.3390/cancers11091317